Molecular mechanism of respiratory syncytial virus fusion inhibitors

Nature Chemical Biology

Volumn 12, Issue 2, 2016, Pages 87-93

  Battles, Michael B ^a   Langedijk, Johannes P ^b   Furmanova Hollenstein, Polina ^b   Chaiwatpongsakorn, Supranee ^c   Costello, Heather M ^c   Kwanten, Leen ^b   Vranckx, Luc ^b   Vink, Paul ^d   Jaensch, Steffen ^d   Jonckers, Tim H M ^b   Koul, Anil ^b   Arnoult, Eric ^e   Peeples, Mark E ^c,f   Roymans, Dirk ^b   McLellan, Jason S ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Janssen Research and Development   (Netherlands)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 1,3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL]METHYL] 2H IMIDAZO[4,5 C]PYRIDIN 2 ONE; 2 [[2 [[1 (2 AMINOETHYL) 4 PIPERIDINYL]AMINO] 4 METHYL 1H BENZIMIDAZOL 1 YL]METHYL] 6 METHYL 3 PYRIDINOL; 2 [[6 [[[2 (3 HYDROXYPROPYL) 5 METHYLPHENYL]AMINO]METHYL] 2 [(3 MORPHOLINOPROPYL)AMINO] 1 BENZIMIDAZOLYL]METHYL] 6 METHYL 3 PYRIDINOL; BTA 9881; JNJ 49153390; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; VIRUS FUSION PROTEIN; ANTIVIRUS AGENT;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL FUSION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG MECHANISM; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IN VITRO STUDY; ISOTHERMAL TITRATION CALORIMETRY; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; STOICHIOMETRY; ANTAGONISTS AND INHIBITORS; BIOASSAY; CHEMISTRY; COLORIMETRY; DRUG EFFECTS; MOLECULAR MODEL; REAL TIME POLYMERASE CHAIN REACTION;

ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; COLORIMETRY; HUMANS; MODELS, MOLECULAR; REAL-TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

EID: 84955189773     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1982     Document Type: Article

References (41)

1. Nair, H. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375, 1545-1555 (2010).
2. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
3. Falsey, A.R., Hennessey, P.A., Formica, M.A., Cox, C., Walsh, E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749-1759 (2005).
4. Anderson, L.J. et al. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 31 (suppl. 2): B209-B215 (2013).
5. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537 (1998).
6. Smart, K.A., Lanctôt, K.L., Paes, B.A. The cost effectiveness of palivizumab: a systematic review of the evidence. J. Med. Econ. 13, 453-463 (2010).
7. McLellan, J.S., Ray, W.C., Peeples, M.E. Structure and function of respiratory syncytial virus surface glycoproteins. Curr. Top. Microbiol. Immunol. 372, 83-104 (2013).
8. Karron, R.A. et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. USA 94, 13961-13966 (1997).
9. Walsh, E.E., Hruska, J. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J. Virol. 47, 171-177 (1983).
10. McLellan, J.S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013).
11. Liljeroos, L., Krzyzaniak, M.A., Helenius, A., Butcher, S.J. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc. Natl. Acad. Sci. USA 110, 11133-11138 (2013).
12. Yunus, A.S. et al. Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation. Virology 396, 226-237 (2010).
13. Lamb, R.A., Jardetzky, T.S. Structural basis of viral invasion: lessons from paramyxovirus F. Curr. Opin. Struct. Biol. 17, 427-436 (2007).
14. McLellan, J.S., Yang, Y., Graham, B.S., Kwong, P.D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85, 7788-7796 (2011).
15. Zhao, X., Singh, M., Malashkevich, V.N., Kim, P.S. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Natl. Acad. Sci. USA 97, 14172-14177 (2000).
16. Cianci, C. et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. 48, 413-422 (2004).
17. Andries, K. et al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res. 60, 209-219 (2003).
18. Douglas, J.L. et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J. Virol. 77, 5054-5064 (2003).
19. Bonfanti, J.F. et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J. Med. Chem. 51, 875-896 (2008).
20. Roymans, D., Koul, A. in Human Respiratory Syncytial Virus Infection (ed. Resch, B.) 197-234 (InTech, 2011).
21. DeVincenzo, J.P. et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N. Engl. J. Med. 371, 711-722 (2014).
22. Roymans, D. et al. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc. Natl. Acad. Sci. USA 107, 308-313 (2010).
23. Douglas, J.L. et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob. Agents Chemother. 49, 2460-2466 (2005).
24. Cianci, C. et al. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc. Natl. Acad. Sci. USA 101, 15046-15051 (2004).
25. Yan, D. et al. Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. Proc. Natl. Acad. Sci. USA 111, E3441-E3449 (2014).
26. Hallak, L.K., Collins, P.L., Knudson, W., Peeples, M.E. Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 271, 264-275 (2000).
27. Morton, C.J. et al. Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay. Virology 311, 275-288 (2003).
28. Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).
29. Mackman, R.L. et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J. Med. Chem. 58, 1630-1643 (2015).
30. Samuel, D. et al. GS-5806 inhibits pre-to post-fusion conformational changes of the RSV fusion protein. Antimicrob. Agents Chemother. 59, 7109-7112 (2015).
31. Hotard, A.L. et al. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis. J. Virol. 89, 512-522 (2015).
32. Madani, N. et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16, 1689-1701 (2008).
33. LaLonde, J.M. et al. Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J. Med. Chem. 55, 4382-4396 (2012).
34. Acharya, P. et al. Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. ACS Chem. Biol. 6, 1069-1077 (2011).
35. Lin, P.F. et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA 100, 11013-11018 (2003).
36. Herschhorn, A. et al. A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat. Chem. Biol. 10, 845-852 (2014).
37. Si, Z. et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. USA 101, 5036-5041 (2004).
38. Russell, R.J. et al. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl. Acad. Sci. USA 105, 17736-17741 (2008).
39. Luo, G. et al. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J. Virol. 71, 4062-4070 (1997).
40. Bodian, D.L. et al. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 32, 2967-2978 (1993).
41. Leneva, I.A., Russell, R.J., Boriskin, Y.S., Hay, A.J. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 81, 132-140 (2009).